High Doses of OnabotulinumtoxinA in Post-stroke Spasticity: a Retrospective Analysis

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2015 Mar 1

PMID 25724294

Citations 18

Authors

Alessio Baricich

Elisa Grana

Stefano Carda

Andrea Santamato

Carlo Cisari

Marco Invernizzi

Affiliations

Soon will be listed here.

Abstract

We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.

Citing Articles

SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication.

Forde G, Brucker B, Ifantides K, Patel A, Mayadev A, Brown T Toxins (Basel). 2024; 16(10).

PMID: 39453196 PMC: 11511055. DOI: 10.3390/toxins16100420.

Multiple sclerosis and spasticity: the role of anaesthetic nerve blocks on rectus femoris muscle. When should stiff knee be treated with botulinum toxin?.

Baricich A, Battaglia M, Borg M, Loro A, Morlino P, Cosenza L J Rehabil Med. 2024; 56:jrm40437.

PMID: 39101677 PMC: 11318643. DOI: 10.2340/jrm.v56.40437.

The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis.

Facciorusso S, Spina S, Picelli A, Baricich A, Francisco G, Molteni F Toxins (Basel). 2024; 16(4).

PMID: 38668609 PMC: 11053519. DOI: 10.3390/toxins16040184.

Botulinum Toxin-A High-Dosage Effect on Functional Outcome and Spasticity-Related Pain in Subjects with Stroke.

Intiso D, Centra A, Gravina M, Chiaramonte A, Bartolo M, Di Rienzo F Toxins (Basel). 2023; 15(8).

PMID: 37624266 PMC: 10467116. DOI: 10.3390/toxins15080509.

Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study.

Baricich A, Battaglia M, Cuneo D, Cosenza L, Millevolte M, Cosma M Front Neurol. 2023; 14:1133390.

PMID: 37090974 PMC: 10117778. DOI: 10.3389/fneur.2023.1133390.

References

Francisco G . Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004; 83(10 Suppl):S30-7. DOI: 10.1097/01.phm.0000141128.62598.81. View

Picelli A, Lobba D, Midiri A, Prandi P, Melotti C, Baldessarelli S . Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil. 2013; 28(3):232-42. DOI: 10.1177/0269215513497735. View

Goldstein E . Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol. 2006; 21(3):189-92. DOI: 10.2310/7010.2006.00041. View

Brashear A, Gordon M, Elovic E, Kassicieh V, Marciniak C, Do M . Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347(6):395-400. DOI: 10.1056/NEJMoa011892. View

Kanovsky P, Slawek J, Denes Z, Platz T, Comes G, Grafe S . Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43(6):486-92. DOI: 10.2340/16501977-0796. View

Martin A, Abogunrin S, Kurth H, Dinet J . Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat. 2014; 10:111-22. PMC: 3905098. DOI: 10.2147/NDT.S53913. View

Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A . Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection. Eur J Phys Rehabil Med. 2014; 51(4):353-9. View

Santamato A, Panza F, Ranieri M, Frisardi V, Micello M, Filoni S . Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna). 2012; 120(3):469-76. DOI: 10.1007/s00702-012-0892-x. View

Ghasemi M, Salari M, Khorvash F, Shaygannejad V . A literature review on the efficacy and safety of botulinum toxin: an injection in post-stroke spasticity. Int J Prev Med. 2013; 4(Suppl 2):S147-58. PMC: 3678211. View

10.

Wissel J, Ward A, Erztgaard P, Bensmail D, Hecht M, Lejeune T . European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009; 41(1):13-25. DOI: 10.2340/16501977-0303. View

11.

Varghese-Kroll E, Elovic E . Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil. 2009; 88(6):495-9. DOI: 10.1097/PHM.0b013e3181a5b056. View

12.

Santamato A, Micello M, Panza F, Fortunato F, Baricich A, Cisari C . Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. J Neurol Sci. 2014; 347(1-2):39-43. DOI: 10.1016/j.jns.2014.09.016. View

13.

Naumann M, Albanese A, Heinen F, Molenaers G, Relja M . Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006; 13 Suppl 4:35-40. DOI: 10.1111/j.1468-1331.2006.01652.x. View

14.

Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies J, Gordon M . Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002; 83(10):1349-54. DOI: 10.1053/apmr.2002.35474. View

15.

Naumann M, Jankovic J . Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004; 20(7):981-90. DOI: 10.1185/030079904125003962. View

16.

Baker J, Pereira G . The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil. 2013; 27(12):1084-96. DOI: 10.1177/0269215513491274. View

17.

Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C . A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005; 26(1):26-31. DOI: 10.1007/s10072-005-0378-9. View

18.

Henzel M, Munin M, Niyonkuru C, Skidmore E, Weber D, Zafonte R . Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections. PM R. 2010; 2(7):642-6. PMC: 5248984. DOI: 10.1016/j.pmrj.2010.05.002. View

19.

Brin M . Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997; 6:S208-20. DOI: 10.1002/(sici)1097-4598(1997)6+<208::aid-mus15>3.0.co;2-1. View

20.

Biering-Sorensen F, Nielsen J, Klinge K . Spasticity-assessment: a review. Spinal Cord. 2006; 44(12):708-22. DOI: 10.1038/sj.sc.3101928. View